RXI Pharma (RXII) Reports In-Line Q3 EPS

RXI Pharma (NASDAQ: RXII) reported Q3 EPS of ($0.34), in-line with the analyst estimate of ($0.34).

For earnings history and earnings-related data on RXI Pharma (RXII) click here.

You May Also Be Interested In

• Rivian reports record Q3 deliveries, beats estimates, shares rise
• Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
• Reaction roundup: Experts, analysts weigh in on September jobs report